Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- Type: Workshop
- Track: N/A
- Presentations: 17
- Moderators:Yi-Long Wu
- Coordinates: 8/06/2022, 21:00 - 23:59, On-Demand
-
+
WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
23:21 - 23:22 | Author(s): Lin Wu
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-095 - Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.01-093 - ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.01-094 - A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Author(s): Lin Wu- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-158 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-161 - An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-160 - A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
Author(s): Lin Wu- Abstract
Loading... -
+
EP08.02-159 - Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Author(s): Juan Li- Abstract
Loading... -
+
EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Author(s): Ying Cheng- Abstract
Loading...
